Meta-Analysis
Copyright ©The Author(s) 2022.
World J Cardiol. Nov 26, 2022; 14(11): 599-616
Published online Nov 26, 2022. doi: 10.4330/wjc.v14.i11.599
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 PRISMA flow diagram showing outcomes of databases and registers search. SGLT2-I: Sodium-glucose cotransporter 2 inhibitor; Mets: Metabolic syndrome.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Forest plot. A: Highlighting impact of SGLT2-I on FPG compared to placebo; B: SGLT2-I dose subgroup analysis performed for FPG. SGLT2-I: Sodium-glucose cotransporter 2 inhibitor; FPG: Fasting plasma glucose.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Forest plot. A: Highlighting impact of SGLT2-I on SBP compared to placebo; B: SGLT2-I Type subgroup analysis performed for SBP. SGLT2-I: Sodium-glucose cotransporter 2 inhibitor; SBP: Systolic blood pressure.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Forest plot highlighting impact of SGLT2-I on DBP compared to placebo. SGLT2-I: Sodium-glucose cotransporter 2 inhibitor; DBP: Diastolic blood pressure.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Forest plot highlighting impact of SGLT2-I on WC compared to placebo. SGLT2-I: Sodium-glucose cotransporter 2 inhibitor; WC: Waist circumference.
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 Forest plot highlighting the absence of significant impact of SGLT2-I on HDL compared to placebo. SGLT2-I: Sodium-glucose cotransporter 2 inhibitor; HDL: High-density lipoprotein.
Figure 7
Open in New Tab Full Size Figure Download Figure
Figure 7 Forest plot. A: Highlighting impact of SGLT2-I on HgbA1C compared to placebo; B: SGLT2-I Dose subgroup analysis performed for HgbA1C. SGLT2-I: Sodium-glucose cotransporter 2 inhibitor.
Figure 8
Open in New Tab Full Size Figure Download Figure
Figure 8 Forest plot. A: Highlighting impact of SGLT2-I on BW compared to placebo; B: SGLT2-I Type subgroup analysis performed for BW; C: SGLT2-I Dose subgroup analysis performed for BW. SGLT2-I: Sodium-glucose cotransporter 2 inhibitor; BW: Body weight.
Figure 9
Open in New Tab Full Size Figure Download Figure
Figure 9 Forest plot. A: Highlighting impact of SGLT2-I on UA compared to placebo; B: SGLT2-I Type subgroup analysis performed for UA; C: SGLT2-I Dose subgroup analysis performed for UA. SGLT2-I: Sodium-glucose cotransporter 2 inhibitor; UA: Uric acid.